Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jerald Koepke

Allergy & Immunology Highlands Ranch, CO Medical Doctor

NPI 1477524957 CMS profile 112292

9331 S Colorado Blvd Ste 100, Ste 120, Highlands Ranch, CO 80126

Open in the dashboard

General payments

$2,298

102 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jerald Koepke of Highlands Ranch, CO is reported in the CMS Open Payments database as having received $2,298 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $46 1
2022 General $602 22
2021 General $488 21
2020 General $498 24
2019 General $664 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerald Koepke
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jerald Koepke were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Jerald Koepke Allergy & Immunology median Middle half National median
2019 $664 $594 $163–$1,512 $163
2020 $498 $426 $106–$1,233 $114
2021 $488 $638 $157–$1,708 $132
2022 $602 $790 $205–$1,961 $149
2023 $46 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $544 26 payments
  2. CSL Behring $300 11 payments
  3. Genzyme Corporation $262 15 payments
  4. GlaxoSmithKline, LLC. $206 11 payments
  5. Aerin Medical Inc. $139 1 payment
  6. Grifols USA, LLC $124 5 payments
  7. kaleo, Inc. $109 5 payments
  8. Pfizer Inc. $88 4 payments
  9. Regeneron Healthcare Solutions, Inc. $84 5 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $83 4 payments
  11. Other $358 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,298 102 payments
Products named General payments · program years 2019–2023
  1. DUPIXENT Immunology $527 30 payments
  2. Haegarda $282 10 payments
  3. FASENRA $263 12 payments
  4. SYMBICORT $134 7 payments
  5. AUVI-Q $109 5 payments
  6. Xembify $88 3 payments
  7. DUPIXENT Inflammation And Immunology $84 5 payments
  8. DUPIXENT Immunology $83 5 payments
  9. RUCONEST $83 3 payments
  10. Orladeyo $72 3 payments
  11. Other $663 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record